Abstract:The survivin (BIRC5) expression is very low in normal differentiated adult tissues, but it is one of the most widely upregulated genes in tumor cells. The overexpression of survivin in many cancer types has been positively correlated with resistance to chemotherapy, tumor metastasis, and poor patient survival. Survivin is considered to be a cancer specific biomarker and serves as a potential cancer drug target. In this report, we describe the design and syntheses of a series of novel selective survivin inhibitors based on the hydroxyquinoline scaffold from our previously reported lead compound MX-106. The best compound identified in this study is compound 12b. In vitro, 12b inhibited cancer cell proliferation with an average IC50 value of 1.4 μM, using a panel of melanoma, breast, and ovarian cancer cell lines. The metabolic stability of 12b improved over MX-106 by 1.7-fold (88 vs 51 min in human microsomes). Western blot analyses demonstrated that treatments with 12b selectively decreased survivin protein levels, but negligibly affected other closely related members in the IAP family proteins, and strongly induced cancer cell apoptosis. In vivo, compound 12b effectively inhibited melanoma tumor growth when tested using a human A375 melanoma xenograft model. Further evaluation using an aggressive, orthotopic ovarian cancer mouse model showed that 12b was highly efficacious in suppressing both primary tumor growth in ovaries and tumor metastasis to multiple peritoneal organs. Collectively, results in this study strongly suggest that the hydroxyquinoline scaffold, represented by 12b and our earlier lead compound MX-106, has abilities to selectively target survivin and is promising for further preclinical development.

Small Molecule Inhibitors Targeting the "Undruggable" Survivin: The Past, Present, and Future from a Medicinal Chemist's Perspective

Small Molecule Inhibitors Targeting the “undruggable” Survivin: the Past, Present, and Future from a Medicinal Chemist’s Perspective

Survivin Small Molecules Inhibitors: Recent Advances and Challenges

Small-molecule Antagonists of Survivin: a New Strategy of Oncotherapy and Chemoprevention

Survivin as a Therapeutic Target for the Treatment of Human Cancer

Design, Synthesis And Structure-Activity Relationship Studies Of Novel Survivin Inhibitors With Potent Anti-Proliferative Properties

Recent Advances in Research on Survivin and Its Moecular Antagonists

A key regulator of mitosis and apoptosis:Survivin,as a novel target for anticancer drug therapeutics

Survivin And Tumorigenesis: Molecular Mechanisms And Therapeutic Strategies

Survivin (BIRC5): Implications in cancer therapy

Overview of role of survivin in cancer: expression, regulation, functions, and its potential as a therapeutic target

MicroRNA Regulation and Therapeutic Targeting of Survivin in Cancer.

Pioneering 4,11-Dioxo-4,11-dihydro-1 H-anthra[2,3- d]imidazol-3-ium Compounds as Promising Survivin Inhibitors by Targeting ILF3/NF110 for Cancer Therapy

Synthesis and biological evaluation of selective survivin inhibitors derived from the MX-106 hydroxyquinoline scaffold

Survivin Stable Knockdown by Sirna Inhibits Tumor Cell Growth and Angiogenesis in Breast and Cervical Cancers

Discovering and Characterizing of Survivin Dominant Negative Mutants With Stronger Pro-apoptotic Activity on Cancer Cells and CSCs

Design of novel potent selective survivin inhibitors using 2D-QSAR modeling, molecular docking, molecular dynamics, and ADMET properties of new MX-106 hydroxyquinoline scaffold derivatives

Inhibitor of Apoptosis Protein (IAP) Antagonists in Anticancer Agent Discovery: Current Status and Perspectives.

Pioneering 4,11-Dioxo-4,11-dihydro-1<i>H</i>-anthra[2,3-<i>d</i>]imidazol-3-ium Compounds as Promising Survivin Inhibitors by Targeting ILF3/NF110 for Cancer Therapy

Disulfide Bond Cys30–cys299 and the Fragment “96rimqaplt106”of the Lid Region of Lip2 Are Critical for Its Biocatalytic Activity

Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trials